Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
NCT06523621
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study is unique because it combines different therapies to see how well they work together in treating the disease. Here are some key points about the study:
- The treatment involves using a combination of existing therapies that have shown promise in previous studies.
- Patients will receive the treatment in a controlled environment, allowing researchers to closely monitor its effects.
- The study aims to evaluate how effective this combination is in reducing symptoms and improving the quality of life for patients.
- Researchers are also looking at how well patients tolerate the treatment and any side effects that may occur.
- This study is significant because it could lead to new treatment options for patients who may not have responded well to standard therapies.
Third Opinion AI Generated Synopsis
Trial Summary
This study is designed to evaluate if treatment with adjuvant nivolumab improves depth of response in patients with relapsed refractory multiple myeloma (RRMM) who achieve a less-than-ideal response to idecaptagene vicleucel.
This study is designed to evaluate if treatment with adjuvant nivolumab improves depth of response in patients with relapsed refractory multiple myeloma (RRMM) who achieve a less-than-ideal response to idecaptagene vicleucel.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
